Taysha Gene Therapies (NASDAQ:TSHA) Upgraded to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Taysha Gene Therapies from “Sell” to “Hold.” Despite mixed analyst views, MarketBeat reports a consensus “Buy” rating and an average price target of $12.75.
• Taysha reported quarterly earnings per share of -$0.10, beating the consensus estimate of -$0.13; analysts forecast full-year EPS of -$0.52.
• Shares opened at $4.10, within a 12-month range of $3.45 to $7.30. Hedge funds and other institutional investors own 77.7% of the stock.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Taysha Gene Therapies in a research note on Monday, September 21st. The Goldman Sachs Group lifted their target price on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a "buy" rating in a report on Tuesday, July 21st. Finally, Wolfe Research assumed coverage on shares of Taysha Gene Therapies in a research note on Thursday, September 17th. They issued an "outperform" rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $12.75.

Taysha Gene Therapies Stock Down 2.6%

TSHA stock opened at $4.10 on Friday. Taysha Gene Therapies has a twelve month low of $3.45 and a twelve month high of $7.30. The company has a quick ratio of 17.76, a current ratio of 17.76 and a debt-to-equity ratio of 0.13. The firm has a market cap of $1.34 billion, a PE ratio of -9.53 and a beta of 1.36. The business has a 50 day moving average of $4.49 and a 200 day moving average of $5.28.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.03. On average, research analysts forecast that Taysha Gene Therapies will post -0.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of hedge funds have recently added to or reduced their stakes in TSHA. Wellington Management Group LLP boosted its stake in shares of Taysha Gene Therapies by 534.7% in the 2nd quarter. Wellington Management Group LLP now owns 3,975,605 shares of the company's stock worth $27,074,000 after buying an additional 3,349,244 shares during the last quarter. Pictet Asset Management Holding SA increased its position in Taysha Gene Therapies by 19.6% during the third quarter. Pictet Asset Management Holding SA now owns 3,313,062 shares of the company's stock valued at $16,135,000 after acquiring an additional 542,361 shares during the last quarter. ADAR1 Capital Management LLC lifted its holdings in Taysha Gene Therapies by 19.4% in the first quarter. ADAR1 Capital Management LLC now owns 2,979,429 shares of the company's stock valued at $13,318,000 after acquiring an additional 483,620 shares during the period. Rice Hall James & Associates LLC lifted its holdings in Taysha Gene Therapies by 53.0% in the first quarter. Rice Hall James & Associates LLC now owns 1,944,671 shares of the company's stock valued at $8,693,000 after acquiring an additional 674,026 shares during the period. Finally, Bank of America Corp DE boosted its position in Taysha Gene Therapies by 45.5% in the first quarter. Bank of America Corp DE now owns 1,677,046 shares of the company's stock worth $7,496,000 after purchasing an additional 524,366 shares during the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies is a biotechnology company focused on developing gene therapies for rare, genetically driven diseases. Based in Dallas, Texas, the company was founded in 2019 and has built its programs around adeno-associated virus delivery technology. The company's lead program, TSHA-102, is an investigational gene therapy being developed for Rett syndrome, a rare neurological disorder. Taysha's research has also included gene therapy programs for other rare diseases, including giant axonal neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.